1Vestbo J, Hurd SS, Agusti AG, et al. Global initiative for chronic obstructive lung disease., global strategy for the diagnosis, management, and prevention of chronic ob- structive pulmonary disease[J]. Am J Respir Crit Care Med, 2013,187(4) :347-365.
2Barnes PJ, Adcock IM. Glucocorticoid resistance in in- flammatory diseases[J]. Lancet, 2009,373 (9678) : 1905- 1917.
3Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacety- lase 2-mediated deacetylation of the glucocorticoid receptor enables NF-~E suppressio[J]. JExp Med, 2006,203 (1) ~ 7- 13.
4Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages[J3. J Exp Med, 2004,200 (5) : 689- 695.
5Ford PA,Durham AL,Russdl RE,et al. Treatment effects of Low-Dose theophylline combined with an inhaled corticoste- roid in COPD[J]. Chest,2010,137(6) :1338-1344.
7Malhotra D, Thimmulappa RK, Mercado N, et al. Deni- trosylation of HDAC2 by targeting Nrf2 restores glu- cocorticosteroid sensitivity in macrophages from COPD patients[J]. J Clin Invest,2011,121 (11) :4289.
8Altenburg J,De Graaff CS,Van Der Werf TS, et al. Im- munomodulatory effects of macrolide antibiotics-part 1: biological mechanisms[J]. Respiration, 2011,81 (1) : 67- 74.
9Marjanovi N,Bosnar M, Michielin F,et al. Macrolide anti- biotics broadly and distinctively inhibit cytokine and che- mokine production by COPD sputum cells in vitro[J]. Pharmacol Res, 2011,63 (5) : 389-397.
